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BACKGROUND Chronic total occlusion (CTO) recanalization is still a
very challenging topic in the ﬁeld of coronary intervention. Data on
the performance of drug eluting stent (DES) with bioresorbable poly-
mer in CTO are limited. The aim of our study is to assess 1-year clinical
outcomes in CTO lesion management in a large worldwide registry.
METHODS In the large, prospective, single-arm, multi-center eNO-
BORI registry, 12139 patients were treated with Nobori DES. Among
them 437 (3.6%) had at least one CTO lesion treated. An independent
clinical events committee adjudicated all endpoint related adverse
events. The primary endpoint was Target Lesion Failure (TLF) at 1 year.
RESULTS CTO patients were on average 60.7 years old and 82.4% are
male, with a history of myocardial infarction, PTCA and cardiac sur-
gery of 45.7%, 34.1% and 6.7%, respectively. 77.6% patients were
hypertensive and 29.5% had diabetes. 68.7% patients were presented
with stable angina while 13.3% had acute coronary syndrome. Lesions
were located in the LAD (38.5%), RCA (37.6%), and LCX (22.6%).
Multiple vessels were treated in 35.0% of patients (2.21.4 lesions
treated per patient) with an average of 1.50.8 stents per lesion.
Among all 751 treated lesions, 614 (81.8%) were complex B2/C type
lesions, with 17.2% Ostial lesion, 49.1% moderate or severe calciﬁed
lesion, 62.6% CTO lesion, 2.8% had thrombus present and 7.3% were
bifurcation. Pre- and post-dilatation were performed in 85.5% and
36.4% of lesions, respectively. Antegrade approach was chosen in the
majority of procedures (88.2%), and a high frequency of single wire
technique (79.0%) was used compared to parallel wire (13.4%) and
seesaw wire (1.5%) techniques. Several other techniques were used for
CTO treatment including CTO dedicated wires (38.4%), OTW balloon
(8.5%), microcatheter (26.8%), rotational atherectomy (2.0%), cutting
balloon (2.9%) and balloon dilatation only (4.7%). IVUS guidance was
performed in 7.4% of patients. The average contrast volume and ﬂu-
oro time were 269124mL and 37.237.9 minutes, respectively. Pro-
cedural success rate was 98.2%. At 1 year follow up, 16 (3.7%) out of
437 patients had TLF. Three cardiac deaths (0.7%) and 7 target lesion
revascularizations (1.6%) were reported at one year follow-up -
together with 7 (1.6%) myocardial infarctions. A total of 80.8% of the
patients were angina free at 1 year. Only 1 stent thrombosis (deﬁnite
plus probable) was reported up to 1 year.
CONCLUSIONS Treatment of CTO with Nobori DES showed encour-
aging outcomes, although we cannot completely exclude the possi-
bility that there might be underreporting of events, particularly
periprocedural MIs might exist. One-year clinical outcomes suggest
that this stent is a valuable treatment option for patients with CTO
who are considered candidates for coronary interventions.
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BACKGROUND Although second generation drug-eluting stents (DES)
have improved angiographic and clinical outcomes over ﬁrst-genera-
tion DESs, clinical efﬁcacy and safety of second-generation DES for
the percutaneous coronary intervention of chronic total occlusion
(CTO) were not well deﬁned.
METHODS We evaluated the 3-years clinical outcomes of 546 patients
treated with second generation DES (everolimus- or zotarolimus-
eluting stent) and 503 with ﬁrst generation DES (sirolimus- or pacli-
taxel- eluting stent) for CTO in Asan Medical Center from 2004 to
2013. The primary endpoint was the incidence of major adverse car-
diac events (MACE) at 3 years, deﬁned as a composite of death,Q-wave myocardial infarction (MI), or target-vessel revascularization
(TVR).
RESULTS The 3-year overall mortality of the second and ﬁrst gener-
ation DES groups were not signiﬁcantly different. (6.41.2% vs.
4.10.9%, P¼0.12). After multivariable adjustment, there was no sig-
niﬁcant difference between patients who received second generation
and ﬁrst generation DES for the risk of MACE. (Hazard ratio [HR] 1.35,
95% conﬁdence interval [CI] 0.85-2.12, P ¼0.20). The risk of death (HR
1.61, 95% CI 0.86-2.99, P ¼0.14), Q-wave MI (HR 1.41, 95% CI 0.40-
4.95, P ¼0.59) and TVR (HR 0.86, 95% CI 0.41-1.76, p¼0.67) were
similar between the two groups. The incidence of deﬁnite/probable
stent thrombosis was comparable (0.7% vs.1.0%, p¼0.65) throughout
the follow-up period.Outcomes Hazard ratio 95% conﬁdence interval P valueMACE 1.35 0.85-2.12 0.20Death 1.61 0.86-2.99 0.14Cardiac death 1.72 0.75-3.95 0.20Myocardial infarction 1.41 0.40-4.95 0.59Death and myocardial infarction 1.50 0.86-2.73 0.16Target vessel revascularization 0.86 0.41-1.76 0.67Any repeat revascularization 1.11 0.64-1.93 0.72MACE ¼ major adverse cardiovascular event.CONCLUSIONS The 3-year clinical outcomes after CTO intervention
using second generation DESs were not signiﬁcantly different from
those using ﬁrst generation DESs.
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BACKGROUND Bioabsorbable polymer drug-eluting stents (DES)
represent an indisputable improvement over ﬁrst-generation DES
